Department of Orthopaedics, University of Rochester Medical Center, Rochester, New York.
Division of Orthopaedics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
J Bone Joint Surg Am. 2019 Jan 16;101(2):119-126. doi: 10.2106/JBJS.18.00657.
Effective postoperative analgesia remains a priority in orthopaedic surgery, but concerns with regard to opioid diversion and misuse have brought overdue attention to improving opioid stewardship. Normative data for postoperative pain and opioid use are needed to guide and balance these dual priorities. We aimed to characterize postoperative pain and opioid use for an archetypal pediatric orthopaedic procedure: closed reduction and percutaneous pinning of a supracondylar humeral fracture.
Children at a single pediatric trauma center who underwent closed reduction and percutaneous pinning of a supracondylar humeral fracture were enrolled and were prospectively followed. Validated pain scores (Wong-Baker FACES Pain Rating Scale) and opioid utilization data were collected using an automated text message-based protocol on postoperative days 1 to 7, 10, 14, and 21. Data were analyzed with descriptive and univariate statistics.
Eighty-one patients with a mean age (and standard deviation) of 6.1 ± 2.1 years (62% of whom were male) were enrolled, including 53.1% who had Type-II fractures and 46.9% who had Type-III fractures. The mean pain ratings were highest on arrival to the emergency department (3.5 ± 3.5 points) and the morning of postoperative day 1 (3.5 ± 2.4 points). By postoperative day 3, the mean pain rating decreased to <2 (1.8 ± 1.8 points) and the mean opioid doses decreased to <1 dose (0.8 ± 1.2 doses). Postoperative opioid use decreased in parallel to reported pain (r = 0.972; p < 0.001). The interquartile range of opioid use was 1 to 7 doses, and patients used only 24.1% of the prescribed opioids (mean, 4.8 ± 5.6 doses used and 19.8 ± 7.1 doses prescribed). There was no significant difference (p > 0.05) in pain ratings or opioid use by fracture classification, age, or sex.
Following closed reduction and percutaneous pinning for supracondylar humeral fracture, pain levels and opioid usage decrease to a clinically unimportant level by postoperative day 3. Patients who report pain scores of ≥6 points following discharge are outliers and should be screened for compartment syndrome or ischemia. Patients used <25% of prescribed opioid medication, suggesting the potential for overprescription and opioid diversion. A prescription for 7 opioid doses after discharge should allow adequate postoperative analgesia in the majority of patients while improving narcotic stewardship.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
有效的术后镇痛仍然是骨科手术的首要任务,但由于担心阿片类药物的转移和滥用,人们对改善阿片类药物管理的关注度已经提高。需要有术后疼痛和阿片类药物使用的规范数据来指导和平衡这两个优先事项。我们旨在描述一种典型的儿科骨科手术(即肱骨髁上骨折闭合复位和经皮克氏针固定术)的术后疼痛和阿片类药物使用情况。
在一家儿科创伤中心,对接受肱骨髁上骨折闭合复位和经皮克氏针固定术的患儿进行前瞻性随访,并登记在册。使用基于自动文本消息的方案,在术后第 1 至 7 天、第 10 天、第 14 天和第 21 天收集有效的疼痛评分(Wong-Baker FACES 疼痛评定量表)和阿片类药物使用数据。采用描述性和单变量统计方法对数据进行分析。
共纳入 81 名平均年龄(标准差)为 6.1 ± 2.1 岁(62%为男性)的患儿,其中 53.1%为Ⅱ型骨折,46.9%为Ⅲ型骨折。疼痛评分最高的是到达急诊科时(3.5 ± 3.5 分)和术后第 1 天早上(3.5 ± 2.4 分)。到术后第 3 天,疼痛评分平均降至<2(1.8 ± 1.8 分),阿片类药物剂量平均降至<1 剂(0.8 ± 1.2 剂)。术后阿片类药物的使用与报告的疼痛呈平行下降趋势(r = 0.972;p < 0.001)。阿片类药物使用的四分位间距为 1 至 7 剂,患者仅使用了处方阿片类药物的 24.1%(平均使用 4.8 ± 5.6 剂,处方 19.8 ± 7.1 剂)。骨折类型、年龄或性别对疼痛评分或阿片类药物使用无显著差异(p > 0.05)。
肱骨髁上骨折闭合复位和经皮克氏针固定术后,疼痛水平和阿片类药物使用在术后第 3 天降至临床无足轻重的水平。出院后疼痛评分≥6 分的患者为异常值,应筛查有无骨筋膜室综合征或缺血。患者使用的处方阿片类药物不足 25%,表明可能存在过度处方和阿片类药物转移。出院后开具 7 剂阿片类药物的处方,可在大多数患者中提供足够的术后镇痛,同时改善阿片类药物的管理。
治疗性 IV 级。欲了解完整的证据水平描述,请参见作者须知。